Xenon filed a 2025 operating loss of $373.1 million, a 2025 net loss of $345.9 million and Q1 2026 cash of $545.9 million. The thesis depends on clinical execution, regulatory progress and how long the balance sheet can fund development.
Xenon Pharmaceuticals: epilepsy pipeline optionality with the cash clock in view
NASDAQXENECoverage BootstrapXenon Pharmaceuticals Inc.
Thesis summary
Xenon filed a 2025 operating loss of $373.1 million, a 2025 net loss of $345.9 million and Q1 2026 cash of $545.9 million. The thesis depends on clinical execution, regulatory progress and how long the balance sheet can fund development.
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.